

XXXI IACRLRD SYMPOSIUM 2023

31 AUGUST - 01 SEPTEMBER - 02 SEPTEMBER

BOLOGNA, ROYAL HOTEL CARLTON

PRESIDENT

GIOVANNI MARTINELLI

VICE PRESIDENT

CLAUDIO CERCHIONE

GENERAL SECRETARY

GIUSEPPE SAGLIO (until 2023)

ALI BAZARBACHI (from 2023)

TOPICS:

- ACUTE LYMPHOCYTIC LEUKEMIA
- ACUTE MYELOID LEUKEMIA
- CAR-T CELL AND GENE THERAPIES
- CHRONIC MYELOID LEUKEMIA
- LYMPHOPROLIFERATIVE DISORDERS
- MYELOPROLIFERATIVE NEOPLASMS
- MYELOYDYSPLASTIC SYNDROMES
- MULTIPLE MYELOMA
- SYSTEMIC MASTOCYTOSIS
- VIRUS, INFLAMMATION AND CANCER



WITH PATRONAGE



ALMA MATER STUDIORUM
UNIVERSITÀ DI BOLOGNA



SUMMARY

- 6** **SCIENTIFIC RATIONALE**
- 8** **CHAIRS**
- 9** **SCIENTIFIC COMMITTEE**
- 10** **THURSDAY, AUGUST 31ST**
- 12** **FRIDAY, SEPTEMBER 1ST**
- 15** **SATURDAY, SEPTEMBER 2ND**

Dear friends and colleagues,

We are pleased and proud to invite you to the XXXI Symposium of the International Association for Comparative Research on Leukemia and Related Diseases IACRLRD on August 31 and September 1 and 2, 2023. The Symposium will be held in Bologna, Italy, and one more time assembles many leaders in the field of hematological malignancies. Furthermore, it promises to become another outstanding event in the history of our association.

The symposia takes place at various sites worldwide every two years, and this time it will be at the great site of Bologna City, in Italy. The comparative aspect combines physicians, veterinarians, and scientists in basic research to promote research and improve outcome in leukemia and related diseases worldwide.

The recent Covid-19 worldwide pandemic highlights the importance of networking between researchers in all fields of medicine. In the meantime, it promotes the integration of knowledge on the virus, inflammation, and hematological malignancies. The availability of genome sequences in humans and animal species opens up new avenues for comparative research and novel therapeutic approaches.

Besides using conventional treatment strategies, such as chemotherapeutic drugs and radiotherapy, that have now totally become personalized, immunotherapy is now one of the more efficient strategies to treat cancer. Virus transformation of Chimeric antigen receptor (CAR) T cells could eliminate the population of cancer cells by reinforcing the host's immune system potential against cancer cells or selectively targeting various types of tumors.

Oncolytic virotherapy (OV) is a new cancer treatment modality using competent or genetically engineered viruses to replicate in tumor cells selectively.

The Symposium will provide overview sessions on the pathogenesis of leukemias and lymphomas with particular attention to its

translation into clinical practice. Partnership with industry is integrated, as documented by the satellite symposia.

Several Memorial Lectures will highlight some of the most significant recent developments in leukemia and biomedicine. After each lecture, interactive discussion rounds with the memorial lecturers provided an opportunity for young scientists.

Recent developments in vaccination against tumors or chronic viral diseases such as HPV or HZV infection will complete the program.

We hope that symposium participants will leave with a comprehensive overview of some significant recent developments in leukemia and related diseases concerning pathogenesis and novel therapeutic approaches. The organizing team will try hard to provide a supportive atmosphere. We wish every participant a fruitful and stimulating attendance.

Giovanni Martinelli

President of IACRLRD Symposium 2023

CHAIRS

Claudio **Cerchione**

Meldola (FC), Italy

Giovanni **Martinelli**

Meldola (FC), Italy

Gerardo **Musuraca**

Meldola (FC), Italy

SCIENTIFIC COMMITTEE

Zeba **Aziz**

Lahore, Pakistan

Ali **Bazarbachi**

Beirut, Lebanon

Luigi **Chieco Bianchi**

Padua, Italy

Daniela **Cilloni**

Turin, Italy

Vincenzo **Ciminale**

Padua, Italy

Rüdiger **Hehlmann**

Manheim, Germany

Roland **Mertelsmann**

Freiburg, Germany

Pia **Raanani**

Petah Tikva, Israel

Giuseppe **Saglio**

Turin, Italy

13:00 – 13:30 WELCOME AND INTRODUCTION TO THE SYMPOSIUM

Claudio Cerchione, Giovanni Martinelli, Gerardo Musuraca

13:30 – 14:00 INTRODUCTION LECTURE

The past and the present of IACRLRD

Luigi Chieco Bianchi

14:00 – 14:45 FRANCESCO LO COCO MEMORIAL LECTURE

Chairman: Zeba Aziz

14:00 – 14:15 Introduction

Eduardo Rego

14:15 – 14:45 NPM1: a never ending story

Brunangelo Falini

14:45 – 16:15 SESSION I

VIRUS, INFLAMMATION AND CANCER

Chairman and Discussant: Vincenzo Ciminale

14:45 – 15:00 Targeting virus-infected T cells in lymphoproliferative disorders

Toshiki Watanabe

15:00 – 15:15 Clonal hematopoiesis and thromboinflammation

Alessandro Lucchesi

15:15 – 15:30 Covid 19, Dengue and Chagas'disease infections in hematological patients in Brazil

Carmino de Souza

15:30 – 15:45 Modulation of vascular inflammation in hematology: CD47 blockade and BET inhibition

Nicholas Leeper

15:45 – 16:00 Harnessing cell death pathways to target T-cell leukemia: lessons from HTLV-1

Vincenzo Ciminale

16:00 – 16:15 Discussion panel

Chairman and Speakers

16:15 – 17:00 CLARA BLOOMFIELD MEMORIAL LECTURE

Chairman: Zeba Aziz

16:15 – 16:30 Introduction

Zeba Aziz

16:30 – 17:00 Clara Bloomfield: A force majeure

Robert P. Gale

17:00 – 18:00 Best Oral abstracts from young researchers

Chairman: Claudio Cerchione

18:00 Opening Ceremony and Welcome Cocktail

09:00 – 10:30 SESSION II

VIRUS: FRIENDS OR ENEMIES (CAR-T CELL AND GENE THERAPIES)

Chairman and Discussant: Manel Juan Otero

09:00 – 09:15 Sheba point of care CAR-T cells in hematological malignancies

Arnon Nagler

09:15 – 09:30 The chinese road to CAR-T cell therapy

Xiao-Jun Huang

09:30 – 09:45 The Italian experience on academic CAR-T cells

Concetta Quintarelli

09:45 – 10:00 The experience of a hospital in Barcelona. Can it contribute to define a road to make the access and availability of CAR-T therapies a reality in Europe?

Manel Juan Otero

10:00 – 10:15 Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β -thalassemia: a phase I trial

Aurelio Maggio

10:15 – 10:30 Discussion panel

Chairman and Speakers

10:30 – 11:15 JOHN MOLONEY MEMORIAL LECTURE

Chairman: Elena Parovichnikova

10:30 – 10:45 Introduction

Elena Parovichnikova

10:45 – 11:15 Allogeneic stem cell transplantation in hematologic malignancies: where do we stand?

Mohamad Mohty

11:15 – 11:30 Coffee break

11:30 – 12:45 SESSION III

TARGETING APOPTOSIS IN AML AND MDS

Chairman and Discussants: Moshe Mittelman

11:30 – 11:45 The extended use of senolytic drugs in relapsed and *de novo* AML
Giovanni Marconi

11:45 – 12:00 The target of FLT3 in acute leukemias

Antonio Curti

12:00 – 12:15 The high risk in *de novo* patients treated with new drugs

Fabio Guolo

12:15 – 12:30 MDS 2023: Challenges in diagnosis and treatment

Moshe Mittelman

12:30 – 12:45 Discussion panel

Chairman and Speakers

12:45 – 13:30 CHARLOTTE FRIEND MEMORIAL LECTURE

Chairman: Luigi Chieco Bianchi

12:45 – 13:00 Introduction

Arnon Nagler

13:00 – 13:30 CAR-T cell therapy: new perspectives in hematological malignancies and solid tumors

Franco Locatelli

13:30 – 14:30 Lunch and Poster walking

Chairman: TBD

14:30 – 15:30 SESSION IV

ALL: PRESENT AND UPCOMING THERAPIES

Chairman and Discussant: Robin Foà

14:30 – 14:45 Chemo free therapy in Ph-positive ALL: possible?

Robin Foà

14:45 – 15:00 Mono and bispecific antibodies in ALL

Cristina Papayannidis

15:00 – 15:15 Old and new TKIs inhibitors in Ph-positive ALL

Elias Jabbour

15:15 – 15:30 Discussion panel

Chairman and Speakers

15:30 – 16:15 HOWARD TEMIN MEMORIAL LECTURE

Chairman: Rüdiger Hehlmann

15:30 – 15:45 Introduction

Rüdiger Hehlmann

15:45 – 16:15 New paradigms in the prevention of retrovirus infection

Genoveffa Franchini

16:15 – 16:30 *Coffee break*

16:30 – 18:00 SESSION V

NEW THERAPIES IN MPNs

Chairman and Discussants: Alessandro Vannucchi

16:30 – 16:45 New insights into WHO classification of myeloid neoplasms

Tariq Mughal

16:45 – 17:00 The prognostic role of cancer gene mutations in MPNs

Paola Guglielmelli

17:00 – 17:15 Update management of MPNs

Francesca Palandri

17:15 – 17:30 Treatment landscape for MPNs

Alessandro Vannucchi

17:30 – 17:45 Update in Polycythemia vera

Tiziano Barbui

17:45 – 18:00 Discussion panel

Chairman and Speakers

18:00 – 18:45 YOHEI ITO MEMORIAL LECTURE

Chairman: Jean El Cheikh

18:00 – 18:15 Introduction

Jean El Cheikh

18:15 – 18:45 Update on Multiple Myeloma therapy

Angelo Maiolino

18:45 – 19:45 SYMPOSIUM

SYSTEMIC MASTOCYTOSIS

Chairman: Alessandro Vannucchi

18:45 – 19:00 Deciphering the Mastocytosis world

Daniela Cilloni

19:00 – 19:15 Personalized precision medicine and related treatment algorithms in Mastocytosis

Peter Valent

19:15 – 19:30 Advanced Systemic Mastocytosis: new treatments

Cristina Papayannidis

19:30 – 19:45 Discussion

09:00 – 10:15 SESSION VI

NEW TOOLS IN THE TREATMENT OF LYMPHOPROLIFERATIVE DISEASES: MONO AND BISPECIFIC ANTIBODIES

Chairman and Discussant: Umberto Vitolo

09:00 – 09:15 Bispecific antibodies in the treatment of diffuse large B cells lymphomas: challenging the reign of CAR T cells

Gerardo Musuraca

09:15 – 09:30 The model of diffuse large B cells lymphomas in dogs

Luca Aresu

09:30 – 09:45 Bispecific antibodies in the treatment of Follicular Lymphoma

Stefano Luminari

09:45 – 10:00 Anti CD30 in hematological malignancies

TBD

10:00 – 10:15 Discussion panel

Discussant and Speakers

10:15 – 10:30 *Coffee break*

10:30 – 12:00 SESSION VII

NEW THERAPEUTICAL APPROACHES IN LYMPHOPROLIFERATIVE DISEASES

Chairman and Discussants: Antonio Cuneo

10:30 – 10:45 Targeting apoptosis in the treatment of CLL

Carlos Sérgio Chiattone

10:45 – 11:00 BTK inhibitors in CLL treatment

Gianluca Gaidano

11:00 – 11:15 MicroRNAs as potential tools in CLL therapy

Carlo M. Croce

11:15 – 11:30 Treatment of relapsed and refractory CLL

Lydia Scarfò

11:30 – 11:45 Chronic Lymphocytic Leukemia : En route to cure?

Ahmad Ibrahim

11:45 – 12:00 Discussion panel

Discussant and Speakers

12:00 – 12:45 KENNETH MCCREDIE MEMORIAL LECTURE

Chairman: Luigi Chieco Bianchi

12:00 – 12:15 Introduction

Claudio Cerchione

12:15 – 12:45 The present and the future of ALL therapy

Dieter Hoelzer

12:45 – 13:30 IACRLRD General Assembly and Announcement of the

IACRLRD Symposium 2025

13:30 – 14:30 *Lunch*

14:30 – 16:30 SESSION VIII

NEW INSIGHTS IN CML THERAPY

Chairman and Discussant: Fabrizio Pane

14:30 – 14:45 New perspectives in CML therapy

Jane Apperly

14:45 – 15:00 Additional chromosomal abnormalities in CML

Rüdiger Hehlmann

15:00 – 15:15 When, why and how switching TKIs

Carolina Pavlovsky

15:15 – 15:30 CML in low income countries

Hemant Malhotra

15:30 – 15:45 Third line therapy in CML 2023

Gianantonio Rosti

15:45 – 16:00 TKIs treatment discontinuation in CML patients: facts and dreams

Massimo Breccia

16:00 – 16:15 Challenges and solutions for treatment of the elderly patient with CML

Pia Raanani

16:15 – 16:30 Discussion panel

Discussant and Speakers

16:30 – 18:00 SESSION IX

THE REVOLUTION IN MULTIPLE MYELOMA: FROM PREVENTION TO THE CURE

Chairmen and Discussants: Kenneth C. Anderson, Michele Cavo

16:30 – 16:45 Smoldering MM: to treat or not to treat?

Claudio Cerchione

16:45 – 17:00 How to manage Multiple Myeloma in frontline setting

Michele Cavo

17:00 – 17:15 How to integrate CAR-T cell in the treatment of relapsed/refractory Multiple Myeloma: lights and shadows

Elena Zamagni

17:15 – 17:30 From antibody-drug conjugates to trispecific antibodies: which will be the next novelties?

Hans Lee Virtual presentation

17:30 – 17:45 The present and future of Multiple Myeloma: from immunotherapy to the cure

Kenneth C. Anderson Virtual presentation

17:45 – 18:00 Discussion panel

Discussants and Speakers

18:00 – 18:45 CLOSING LECTURE

Chairman: Giuseppe Saglio

18:00 – 18:15 Introduction

Giuseppe Saglio

18:15 – 18:45 Adult T cell leukemia: past, present and future

Ali Bazarbachi

18:45 Adjourn



IACRLRD

International Association
for Comparative Research
on Leukemia and Related Diseases

Graphic Designer: **Mario Titone**
www.mariotitone.com